CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

As of September 22, 2026, CTNM stock price declined to $13.47 with 404,137 million shares trading.

CTNM has a beta of 0.12, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.00 to the broad based SPY ETF.

CTNM has a market cap of $506.76 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWN.

CTNM has underperformed the market in the last year with a price return of +7.8% while the SPY ETF gained +17.8%. However, in the short term, CTNM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.8% vs +3.9% return in SPY. But in the last 2 weeks, CTNM shares have been beat by the market, returning -19.3% compared to an SPY return of +0.8%.

CTNM support price is $12.98 and resistance is $14.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.